Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Shares of Stryker Co. (NYSE:SYK - Get Rating) have been given a consensus rating of "Buy" by the twenty-one brokerages that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $291.88.

SYK has been the subject of a number of research reports. BTIG Research boosted their price objective on Stryker from $273.00 to $278.00 in a research note on Monday, April 18th. Sanford C. Bernstein upgraded Stryker from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $288.00 to $295.00 in a research report on Wednesday, March 16th. Truist Financial cut their price objective on Stryker from $296.00 to $280.00 in a research report on Monday, May 2nd. TheStreet cut Stryker from a "b" rating to a "c+" rating in a research report on Monday, May 2nd. Finally, Evercore ISI reiterated an "outperform" rating and issued a $284.00 price objective on shares of Stryker in a research report on Tuesday, March 15th.

Shares of NYSE SYK opened at $194.09 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.18 and a debt-to-equity ratio of 0.92. Stryker has a twelve month low of $193.66 and a twelve month high of $281.16. The stock has a 50 day moving average of $237.08 and a two-hundred day moving average of $251.71. The stock has a market cap of $73.40 billion, a P/E ratio of 36.90, a P/E/G ratio of 2.18 and a beta of 0.99.

Stryker (NYSE:SYK - Get Rating) last issued its quarterly earnings data on Thursday, April 28th. The medical technology company reported $1.97 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.04. Stryker had a return on equity of 24.09% and a net margin of 11.56%. The company had revenue of $4.30 billion during the quarter, compared to analysts' expectations of $4.19 billion. During the same quarter in the previous year, the business earned $1.93 earnings per share. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. As a group, research analysts predict that Stryker will post 9.64 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be issued a dividend of $0.695 per share. The ex-dividend date is Wednesday, June 29th. This represents a $2.78 annualized dividend and a dividend yield of 1.43%. Stryker's payout ratio is currently 52.85%.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Stryker by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 28,898,295 shares of the medical technology company's stock valued at $7,725,958,000 after purchasing an additional 245,614 shares in the last quarter. Wellington Management Group LLP grew its stake in Stryker by 11.3% during the 1st quarter. Wellington Management Group LLP now owns 15,370,391 shares of the medical technology company's stock valued at $4,109,274,000 after purchasing an additional 1,561,376 shares in the last quarter. State Street Corp grew its stake in Stryker by 3.0% during the 4th quarter. State Street Corp now owns 13,911,036 shares of the medical technology company's stock valued at $3,729,638,000 after purchasing an additional 402,204 shares in the last quarter. Capital Research Global Investors grew its stake in Stryker by 5.1% during the 1st quarter. Capital Research Global Investors now owns 10,403,668 shares of the medical technology company's stock valued at $2,781,432,000 after purchasing an additional 502,935 shares in the last quarter. Finally, Fundsmith LLP grew its position in shares of Stryker by 3.4% in the 4th quarter. Fundsmith LLP now owns 7,252,688 shares of the medical technology company's stock worth $1,939,514,000 after acquiring an additional 237,196 shares in the last quarter. Institutional investors and hedge funds own 74.52% of the company's stock.

Stryker Company Profile (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Featured StoriesGet a free copy of the StockNews.com research report on Stryker (SYK)Ride Out The Recession With These Dividend Kings MarketBeat: Week in Review 6/13 – 6/17eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term VolatilityHonda's Stock Continues To Fly Under The RadarVuzix Stock Stays Optimistic

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

In today’s episode, Kate welcomes guest Sean Bonner, co-founder of Guild Financial, a self-directed investing and financial education platform, with a special focus on the military community. Sean’s background as a portfolio manager and Navy officer informs his view of the economy and his approach to investing

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.